The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sushinskaya T.V.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Stuklov N.I.

People’s Friendship University of Russia, Ministry of Education of the Russian Federation, Moscow, Russia

Dobrokhotova Iu.É.

Kafedra akusherstva i ginekologii Moskovskogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta

Hemostasis and cancer-associated thrombosis: modern prevention and treatment

Authors:

Sushinskaya T.V., Stuklov N.I., Dobrokhotova Iu.É.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2018;7(4): 64‑72

DOI: 10.17116/onkolog20187464

Views: 30908

Downloaded: 804

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Sushinskaya TV, Stuklov NI, Dobrokhotova IuÉ. Hemostasis and cancer-associated thrombosis: modern prevention and treatment. P.A. Herzen Journal of Oncology. 2018;7(4):64‑72. (In Russ.)
https://doi.org/10.17116/onkolog20187464

МСФ на ЯМ
Close metadata
Recommended articles:
Effe­ctiveness of body weight control using remote digi­tal technologies in various orga­nizational models of primary health care. Medi­cal Technologies. Asse­ssment and Choice. 2024;(1):26-36
The Role of Save­liev V.S. and his School in Deve­lopment of Endo­vascular Prevention of Pulmonary Embo­lism. Journal of Venous Diso­rders. 2024;(1):6-12
Embo­lic Occlusion of Pulmonary Artery by Exte­nded Floating Clots as the most Severe Variant of Venous Thro­mboembolism. Journal of Venous Diso­rders. 2024;(1):14-25
Embo­lism-Threatening Thro­mbosis: Is There Such a Problem?. Journal of Venous Diso­rders. 2024;(1):38-47
The normal sono­graphic picture of the para­tonsillar region and the prerequisites for ultrasound diagnosis of puru­lent pathology of the pharynx. Russian Bulletin of Otorhinolaryngology. 2024;(1):4-9
Primary prevention of computer game addi­ction in students of educational institutions. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):97-103
Methods of pancreatic fibrosis asse­ssment. Russian Journal of Evidence-Based Gastroenterology. 2024;(1):48-57
Gender differences in mental and beha­vioural diso­rders as an impo­rtant stage of cardiovascular diseases prevention in young people. Russian Journal of Preventive Medi­cine. 2024;(3):66-71
Colo­rectal cancer: inci­dence, risk factors, and screening. Russian Journal of Preventive Medi­cine. 2024;(3):93-97
Possibilities of cardiometabolic diseases prevention in women with pregnancy adve­rse outcomes in medi­cal history. Russian Journal of Preventive Medi­cine. 2024;(3):98-103

To date, cancer-associated thrombosis and venous thromboembolism (VTE) are a common cause of death in cancer patients. A number of coagulation abnormalities are well known to develop in malignant neoplasms, providing an increased tendency of patients to thrombosis and hemorrhage. Abnormalities in one or more coagulation tests are common in all cancer patients even without obvious thrombotic and/or hemorrhagic manifestations. The high incidence of hemostatic disorders requires a VTE prevention system at the stages of hospitalization, surgical and certain types of chemotherapy. This has prompted the widespread introduction of standard VTE prevention protocols, which, along with the improvement of anticancer therapies, could improve the survival of cancer patients. However, the rate of VTE mortality has remained high so far and is often not taken into account in the statistics of cancer, because it develops sometimes in late periods after treatment. The presented data may suggest that the problem of thromboembolic events requires the development of new systems for prediction of risks, prevention, approaches to treatment and follow-up of this category of patients. The article analyzes the epidemiology, pathogenesis, laboratory and clinical features of thrombosis in malignant diseases, and methods for VTE diagnosis, prevention, and treatment.

Keywords:

cancer
hemostatic disease
venous thromboembolism
pulmonary embolism
diagnosis
prevention
low-molecular-weight heparins
treatment

Authors:

Sushinskaya T.V.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Stuklov N.I.

People’s Friendship University of Russia, Ministry of Education of the Russian Federation, Moscow, Russia

Dobrokhotova Iu.É.

Kafedra akusherstva i ginekologii Moskovskogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta

List of references:

  1. Jemal A, Bray F, Centeretal MM. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. https://doi.org/10.3322/caac.20107
  2. Alok A, Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010;125(6):490-493. https://doi.org/10.1016/j.thromres.2009.12.023
  3. Trujillo-Santos J, Nieto JA, Tiberio G, Piccioli A, Di Micco P, Prandoni P, Monreal M; RIETE Registry. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100(3):435-439. https://doi.org/10.1160/TH08-02-0125
  4. Sorensen HT, Mellemkjær L, Olsen LH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846-1850. https://doi.org/10.1056/nejm200012213432504
  5. Falanga A, Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie. 2012;32(2):115-125.
  6. Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, Van Der Meer FJM, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66329 cancer patients: record of a linkage study. J Thromb Haemost. 2006;4(3):529-535. https://doi.org/10.1111/j.1538-7836.2006.01804.x
  7. Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and and clinical aspects. J Thromb Haemost. 2013;11(2):223-233. https://doi.org/10.1111/jth.12075
  8. Murchison JT, Wylie L, Stockton DL. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer. 2004;91:92-95. https://doi.org/10.1038/sj.bjc.6601964
  9. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715-722. https://doi.org/10.1001/jama.293.6.715
  10. Karimi M, Cohan N. Cancer-associated thrombosis. Open Cardiovasc Med J. 2010;4:78-82. https://doi.org/10.2174/1874192401004010078
  11. Singh RT, Sousou T, Mohile S, Khorana AA. High rates of symptomatic and incidental thromboembolic events in gastrointestinal cancer patients. J Thromb Haemost. 2010;8(8):1879-81. https://doi.org/10.1111/j.1538-7836.2010.03929.x
  12. Moore RA, Adel N, Riedel E, Bhutani M, Darren R, Feldman DF, Tabbara NE. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29(25):3466-3473. https://doi.org/10.1200/jco.2011.35.5669
  13. Falanga A, Tartari CJ, Marchetti M. Microparticles in tumor progression. Thromb Res. 2012;129(Suppl.1):132-136. https://doi.org/10.1016/s0049-3848(12)70033-6
  14. Falanga A, Marchetti M, Vignoli A, Balducci D. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol. 2003;1(11):673-678. https://doi.org/10.1016/s0049-3848(07)70019-1
  15. Demers M, Wagner DD. Neutrop hilextracellular traps: A new link to cancerassociatedthrombosis and potentialimplications for tumor progression. Oncoimmunology. 2013;2:e22946. https://doi.org/10.4161/onci.22946
  16. Rickles FR, Falanga A. Activation of clotting factors in cancer. Cancer Treat Res. 2009;148:31-41. https://doi.org/10.1007/978-0-387-79962-9_3
  17. Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol. 2009;22(1):49-60. https://doi.org/10.1016/j.beha.2008.12.009
  18. Lyman GH, Kuderer NM. Prevention and treatment of venousthromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines. Thromb Res. 2010;125(Suppl.2):120-127. https://doi.org/10.1016/s0049-3848(10)70029-3
  19. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, et al. American Society of Clinical Oncology Guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490-5505. https://doi.org/10.1200/jco.2007.14.1283
  20. Siragusa S, Armani U, Carpenedo M, Falanga A, Fulfaro F, Imberti D, et al. Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)(1). Thromb Res. 2012;129(5):e171-e176. https://doi.org/10.1016/j.thromres.2011.09.002
  21. Streiff MB. The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. Thromb Res. 2010;125(Suppl.2):S128-S133. https://doi.org/10.1016/s0049-3848(10)70030-x
  22. Mandala M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22(Suppl.6):85-92. https://doi.org/10.1093/annonc/mdr392
  23. Stein PD, Kayali F, Silbergleit A, Hull RD, Olson RE, Meyers FA. Incidence of venous thromboembolism in patients hospitalised with cancer. Am J Med. 2006;119(1):60-68. https://doi.org/10.1016/j.amjmed.2005.06.058
  24. Falanga A, Ofuso FA, Cortellazo S, Delaini F, Consonni R, Caccia R, et al. Preliminary study to identify cancer patients at risk of VTE following major surgery. Br J Haematol. 1993;85(4):745-750. https://doi.org/10.1111/j.1365-2141.1993.tb03218.x
  25. Suvorin PA, Khoronenko VE, Zharkov PA, Baskakov DS. Profilaktika venoznykh tromboembolii u onkologicheskikh bol’nykh. Onkologiya. Zhurnal im. P.A. Gertsena. 2017;6(1):71-75. (In Russ.) https://doi.org/10.17116/onkolog20176171-75
  26. Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, Moia M, Parazzini F, Rossi R, Sonaglia F, Valarani B, Bianchini C, Gussoni G. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 2006;243(1):89-95. https://doi.org/10.1097/01.sla.0000193959.44677.48
  27. Rao MV, Francis CW, Khorana AA. Who’s at risk for thrombosis? Approaches to risk stratifying cancer patients. In: Khorana AA, Francis CW, eds. Cancer-associated thrombosis: New findings in translational science, prevention and treatment. Informa Healthcare, USA; 2008. https://doi.org/10.3109/9781420048001-13
  28. Trinh VQ, Karakiewicz PI, Sammon J, Sun M, Sukumar S, Gervais MK, Shariat SF, Tian Z, Kim SP, Kowalczyk KJ, Hu JC, Menon M, Trinh QD. Venous thromboembolism after major cancer surgery: temporal trends and patterns of care. JAMA Surg. 2014;149(1):43-9. https://doi.org/10.1001/jamasurg.2013.3172
  29. Lyman GH, Eckert L, Wang Y, Wang H, Cohen A. Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. Oncologist. 2013;18(12):1321-1329. https://doi.org/10.1634/theoncologist.2013-0226
  30. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632-634. https://doi.org/10.1111/j.1538-7836.2007.02374.x
  31. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res. 2006;118(5):555-568. https://doi.org/10.1016/j.thromres.2005.10.015
  32. Horsted F, West J, Grainge M. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLOS Med. 2012;9(7):e1001275. https://doi.org/10.1371/journal.pmed.1001275
  33. Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer — a cohort study using linked United Kingdom databases. Eur J Cancer. 2013;49(6):1404-1413. https://doi.org/10.1016/j.ejca.2012.10.021
  34. Khoronenko VE, Chissov VI, Suvorin PA, Baskakov DS. Perioperatsionnaya profilaktika venoznykh tromboembolicheskikh oslozhnenii v planovoi onkokhirurgii. Issledovaniya i praktika v meditsine. 2016;3(4):61-69. (In Russ.) https://doi.org/10.17709/2409-2231-2016-3-4-7
  35. Farge D, Bosquet L, Kassab-Chahmi D, Mismetti P, Elalamy I, Meyer G, Cajfinger F, Desmurs-Clavel H, Elias A, Grange C, Hocini H, Legal G, Mahe I, Quéré I, Levesque H, Debourdeau P; SOR. 2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group. Crit Rev Oncol Hematol. 2010;73(1):31-46. https://doi.org/10.1016/j.critrevonc.2008.12.004
  36. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458-464. https://https://doi.org/10.1001/archinte.166.4.458
  37. Streiff MB, Bockenstedt PL, Cataland SR, Chesney C, Eby C, Fanikos J, Fogarty PF, Gao S, Garcia-Aguilar J, Goldhaber SZ, Hassoun H, Hendrie P, Holmstrom B, Jones KA, Kuderer N, Lee JT, Millenson MM, Neff AT, Ortel TL, Smith JL, Yee GC, Zakarija A. Venous thromboembolic disease. J Natl Compr Canc Netw. 2011;9(7):714-777. https://doi.org/10.6004/jnccn.2011.0062
  38. Menapace LA, Khorana AA. The role of thromboprophylaxis in cancer patients: Emerging data. Curr Opin Hematol. 2010;17(5):450-456. https://doi.org/10.1097/moh.0b013e32833c0760
  39. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907. https://doi.org/10.1182/blood-2007-10-116327
  40. Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L, Clement C, Robinson KS, Lewandowski B. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet. 1997;350(9094):1796-1798. https://doi.org/10.1016/s0140-6736(97)08140-3
  41. O’Connell CL, Boswell WD, Duddalwar V, Caton A, Mark LS, Vigen C, Liebman HA. Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol. 2006;24(30):4928-4932. https://doi.org/10.1200/jco.2006.06.5870
  42. Wells PS, Anderson DR, Rodger M, Ginsberg JS, Kearon C, Gent M, Turpie AG, Bormanis J, Weitz J, Chamberlain M, Bowie D, Barnes D, Hirsh J. Derivation of a simple clinical model to categorize patients’ probability of pulmonary embolism: increasing the model utility with the SimpliRED D-dimer. Thromb Haemost. 2000;83(3):416-420. https://doi.org/10.7326/0003-4819-131-6-199909210-00020
  43. Somonova OV, Madzhuga AV, Elizarova AL. Trombozy i tromboembolii v onkologii. Gazeta Rossiiskogo obshchestva klinicheskoi onkologii. 2015;(4):13-15. (In Russ.)
  44. Sushinskaya TV, Stuklov NI, Dobrokhotova YuE, Petrov AN. Osobennosti gemostaza u bol’nykh rakom sheiki matki na fone lecheniya osnovnogo zabolevaniya. Vestnik poslediplomnogo meditsinskogo obrazovaniya. 2016;(4):31-37. (In Russ.)
  45. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10(10):943-949. https://doi.org/10.1016/s1470-2045(09)70232-3
  46. Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F, Sgouros J, Gardiner E, Wedgwood K, Ettelaie C, Bozas G. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer. 2012;48(9):1283-1292. https://doi.org/10.1016/j.ejca.2011.10.017
  47. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601-609. https://doi.org/10.1056/nejmoa1108898
  48. Rak J, Milsom C, May L, Klement P, Yu J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost. 2006;32:54-70. https://doi.org/10.1055/s-2006-933341
  49. Stuklov NI, ed. Physiology and pathology of hemostasis (Fiziologiya i patologiya gemostaza. Uchebnoe posobie). Moscow: GEOTAR-Media; 2016. (In Russ.)
  50. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846-1850. https://doi.org/10.1056/nejm200012213432504
  51. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ, Edwards RL, Headley E, Kim SH, O’Donnell JF, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung colon, head and neck, and prostate. Final report of VA Cooperative Study no. 75. Cancer. 1984;53(10):2046-2052. https://doi.org/10.1002/10970142(19840515)53:10%3C2046::aidcncr2820531007%3E3.0.co;2-f
  52. Chahinian AP, Propert KJ, Ware JH, Zimmer B, Perry MC, Hirsh V, Skarin A, Kopel S, Holland JF, Comis RL, et al. A randomized trial of anticoagulation of warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Lukemia Group B. J Clin Oncol. 1989;7(8):993-1002. https://doi.org/10.1200/jco.1989.7.8.993

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.